Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Delcath Systems, Inc. DCTH

Healthcare  —  Medical Devices
15.60 (0.48) (2.99%) as of 25 Sep
Market cap
$558.0M
P/E
1,560×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Delcath Systems, Inc. (DCTH) Business Profile

Updated before January 2025

Company Overview

Delcath Systems, Inc. (DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Founded in 1988 and headquartered in New York, USA, Delcath has been at the forefront of developing innovative therapies for liver cancer patients. The company is best known for its proprietary Hepatic Delivery System (HDS), which is designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. Key leadership includes Gerard Michel, who serves as the Chief Executive Officer, bringing extensive experience in the healthcare and pharmaceutical industries. Under his leadership, Delcath has continued to advance its mission of improving outcomes for patients with liver cancer.

Core Business Segments

Delcath Systems operates primarily in the oncology sector, with a focus on liver-directed therapies. The company’s core business segments include:

Hepatic Delivery System (HDS)

The Hepatic Delivery System is Delcath’s flagship product. It is designed to isolate the liver from the body’s circulatory system, allowing for the targeted delivery of high-dose chemotherapy. This system is particularly effective for patients with liver-dominant cancers, including metastatic ocular melanoma and intrahepatic cholangiocarcinoma. The HDS has been approved for use in Europe under the trade name CHEMOSAT® and is undergoing clinical trials in the United States.

Clinical Trials and Research

Delcath is heavily invested in clinical research to expand the indications for its HDS technology. The company is conducting pivotal trials, such as the FOCUS Phase 3 trial, to evaluate the safety and efficacy of its system for treating metastatic ocular melanoma. These trials are critical for gaining regulatory approval in additional markets and for expanding the use of the HDS in treating other liver cancers.

Support Services

Delcath provides comprehensive support services to healthcare providers and patients. These services include training for medical professionals on the use of the HDS, as well as patient education and support programs to ensure optimal outcomes.

Business Model

Delcath’s business model is centered around the development, commercialization, and distribution of its proprietary medical devices and therapies. Revenue is generated through the sale of its CHEMOSAT® system in Europe and through partnerships with healthcare providers and institutions. The company also invests heavily in research and development to expand its product portfolio and to secure regulatory approvals in new markets. Delcath’s approach integrates cutting-edge technology with a patient-centric focus, ensuring that its products meet the highest standards of safety and efficacy.

Strategic Direction

Delcath Systems is committed to expanding its global footprint and advancing its pipeline of innovative therapies. Key strategic initiatives include:

  • Regulatory Approvals: The company is focused on securing FDA approval for its HDS technology in the United States. Successful completion of ongoing clinical trials will be a critical milestone in this effort.
  • Market Expansion: Delcath aims to expand the availability of its CHEMOSAT® system in Europe and to enter new markets in Asia and South America.
  • Product Development: The company is exploring the use of its HDS technology for additional indications, including other types of liver cancer and metastatic diseases.
  • Sustainability Goals: Delcath is committed to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.

Competitive Landscape

Delcath operates in a highly competitive oncology market. Key competitors include:

  • Sirtex Medical: Known for its SIR-Spheres® microspheres, a targeted therapy for liver cancer.
  • BTG International: Offers a range of interventional oncology products, including embolization therapies.
  • Boston Scientific: A major player in the medical device industry, with a focus on interventional oncology.
  • Merck & Co. and Bristol-Myers Squibb: Pharmaceutical giants that offer systemic therapies for liver cancer, such as immunotherapies and targeted drugs.

Despite the competition, Delcath differentiates itself through its unique HDS technology, which offers a targeted approach to liver cancer treatment.

Risk Factors

Delcath faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could hinder the commercialization of its products.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its HDS technology.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers poses a risk of supply chain interruptions.
  • Competition: The oncology market is highly competitive, with numerous established players and new entrants.
  • Financial Risks: As a development-stage company, Delcath may face challenges in securing sufficient funding to support its operations and growth initiatives.

Recent Developments

Delcath has made significant progress in recent years, including:

  • FOCUS Phase 3 Trial: The company announced positive interim results from its FOCUS Phase 3 trial, which is evaluating the safety and efficacy of its HDS technology for treating metastatic ocular melanoma.
  • European Expansion: Delcath has expanded the availability of its CHEMOSAT® system in Europe, with new partnerships and distribution agreements.
  • Leadership Changes: The appointment of Gerard Michel as CEO has brought renewed focus and strategic direction to the company.
  • COVID-19 Impact: Like many companies, Delcath faced challenges due to the COVID-19 pandemic, including delays in clinical trials and disruptions to its supply chain. However, the company has since resumed normal operations and is on track to achieve its strategic goals.

Investment Considerations

Investors considering Delcath Systems should weigh the following factors:

Strengths

  • Innovative Technology: The HDS offers a unique, targeted approach to liver cancer treatment.
  • Growing Market: The global liver cancer market is expected to grow significantly in the coming years, providing opportunities for Delcath.
  • Strong Leadership: The company’s leadership team has extensive experience in the healthcare and pharmaceutical industries.

Risks

  • Regulatory Uncertainty: Delays in obtaining FDA approval could impact the company’s growth prospects.
  • Financial Challenges: As a development-stage company, Delcath may require additional funding to support its operations.
  • Market Competition: The oncology market is highly competitive, with numerous established players.

Conclusion

Delcath Systems, Inc. is a pioneering company in the field of liver-directed cancer therapies. With its innovative HDS technology, the company is well-positioned to address the unmet needs of liver cancer patients. While challenges remain, including regulatory and financial risks, Delcath’s strong leadership and strategic initiatives provide a solid foundation for future growth. As the global demand for effective cancer treatments continues to rise, Delcath is poised to play a significant role in shaping the future of oncology care.